Invest in smarter healthcare

Lumos Diagnostics is a publicly-traded company listed on the Australian Securities Exchange (ASX:LDX).

Register for Lumos investor news and updates.

By entering your email address you are agreeing to our Privacy Policy.

Lumos Diagnostics Holdings Ltd

Key statistics for LDX

Market price
$0.033
Market cap
$-
Volume
82,012
Day low
$0.032
Day high
$0.033
Change
$0.000(0%)
19/06/2024 9:06 am Lumos Receives US$400k Phase 1 Milestone from Hologic 283.0KB (2 pages)
13/06/2024 9:06 am Change of Director's Interest Notice - CR 311.5KB (2 pages)
13/06/2024 9:06 am Change of Director's Interest Notice - SL 317.7KB (2 pages)
04/06/2024 9:06 am Lumos Receives Second US$5 million Hologic IP Payment 245.3KB (3 pages)
28/05/2024 11:05 am March 2024 Appendix 4C - Correction 564.5KB (7 pages)
06/05/2024 8:05 am Lumos Achieves Key Phase 1 Milestone in Hologic Agreement 309.0KB (3 pages)
02/05/2024 2:05 pm Lumos quarterly update video interview with CEO, Doug Ward 221.5KB (2 pages)
01/05/2024 12:05 pm Notification regarding unquoted securities - LDX 21.3KB (8 pages)
23/04/2024 9:04 am Quarterly Activities/Appendix 4C Cash Flow Report 560.2KB (11 pages)
08/04/2024 9:04 am Lumos announces positive FebriDx paediatric study results 374.9KB (4 pages)
02/04/2024 5:04 pm Change in substantial holding 154.1KB (2 pages)
02/04/2024 3:04 pm Application for quotation of securities - LDX 21.1KB (8 pages)
02/04/2024 3:04 pm Section 708A Cleansing Statement 191.8KB (2 pages)
29/02/2024 5:02 pm Change in substantial holding 229.5KB (2 pages)
28/02/2024 8:02 am Half Year Results Investor Presentation 3.8MB (32 pages)
28/02/2024 8:02 am Appendix 4D and Half Year Report 1.4MB (28 pages)
23/02/2024 11:02 am 1H FY24 Results Investor Briefing Invitation 252.9KB (2 pages)
14/02/2024 4:02 pm Change in substantial holding 177.2KB (2 pages)
12/02/2024 9:02 am Lumos Appoints Henry Schein as US Distributor for FebriDx 284.8KB (2 pages)
05/02/2024 9:02 am Lumos Investor Roadshow Presentation 1.5MB (25 pages)
31/01/2024 9:01 am Investor Information Sessions 286.7KB (2 pages)
31/01/2024 9:01 am Quarterly Activities/Appendix 4C Cash Flow Report 599.4KB (12 pages)
19/01/2024 2:01 pm Proposed issue of securities - LDX 30.2KB (6 pages)
19/01/2024 2:01 pm Notification regarding unquoted securities - LDX 34.1KB (9 pages)
17/01/2024 12:01 pm Change in substantial holding 166.3KB (2 pages)
16/01/2024 10:01 am New Hologic Agreements Investor Briefing Presentation 524.2KB (8 pages)
16/01/2024 10:01 am Additional Information Regarding Agreements with Hologic 229.5KB (3 pages)
15/01/2024 2:01 pm Notification of cessation of securities - LDX 27.7KB (6 pages)
15/01/2024 2:01 pm Investor Briefing on new Hologic Agreements 258.3KB (2 pages)
11/01/2024 9:01 am Lumos Signs Major Development and IP Agreements with Hologic 236.3KB (3 pages)
07/12/2023 2:12 pm Change in substantial holding 240.8KB (2 pages)
06/12/2023 8:12 am Commercial Operations Update Webinar Presentation 19.9MB (12 pages)
04/12/2023 1:12 pm Commercial Update Webinar US Product Launch Activities 211.9KB (2 pages)
04/12/2023 8:12 am Lumos Diagnostics FY2023 Full Year Results Webinar 211.0KB (2 pages)
14/11/2023 2:11 pm Becoming a substantial holder from RYD 171.6KB (2 pages)
03/11/2023 3:11 pm Change in substantial holding 216.9KB (2 pages)
03/11/2023 11:11 am Section 708A Cleansing Statement 293.6KB (2 pages)

"Lumos represents a compelling investment opportunity. We have secured strategic partnerships with leading healthcare companies. We are expanding our commercial services division across human health, animal health, food testing and molecular testing. We have secured key FDA clearances for our Point-of-care products. Collectively, our Company has firm foundations for considerable revenue growth."

Doug Ward | Lumos CEO and MD